

ASX Release

Completion of Entitlement Offer

TALi Digital Limited (ASX: TD1, TALi or the Company) is pleased to announce the completion of its 1 for 1 non-renounceable pro-rata entitlement offer of new fully paid ordinary shares (**New Shares**) in TALi to existing eligible shareholders (**Entitlement Offer**) as announced to the ASX on Monday, 21 November 2022.

The Entitlement Offer closed on Thursday, 8 December 2022 and raised a total of \$529,164.74 (before costs) at \$0.002 per New Share.

TALi received valid applications totalling 264,582,040 New Shares. The number of New Shares offered under the Entitlement Offer was 1,357,630,524, resulting in a shortfall of 1,093,048,484 New Shares.

The Entitlement Offer was not underwritten. The Directors have reserved the right to issue any New Shares not taken up by eligible shareholders under the Entitlement Offer within 3 months after the close of the Entitlement Offer in accordance with the shortfall allocation policy set out in the Entitlement Offer Booklet (**Booklet**). As disclosed in section 1.6 of the Booklet, Taylor Collison Limited is assisting the Company in relation to the shortfall.

New Shares issued will rank equally in all respects with existing shares. The New Shares under the Entitlement Offer are expected to be issued today.

If you have any questions in relation to the Entitlement Offer, please contact the Share Registry on 1300 284 664 (within Australia) or +61 2 9698 5414 (outside Australia).

Release authorised by:

The Board of TALi Digital Limited

CONTACT

Mark Simari

Chair
TALi Digital
1300-082-013
mark@akitaconsulting.com.au

Reece Boroughs

Associate Director, Corporate
Taylor Collison Limited
(08) 8217-3900
rboroughs@taylorcollison.com.au

About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence and game-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy and places TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at talidigital.com.